Search Results
Your search for all items matches 34700 pages
Showing 12301 - 12350Comprehensive Overview of How to Start or Improve a Breast Cancer Unit on the Global Stage
Breast cancer is the leading cause of cancer death among women worldwide. As populations age, the incidence of cancer inevitably increases—the World Health Organization has predicted a dramatic increase in global breast cancer cases during the next 15 years. Moreover, breast cancer is increasing in ...
Selpercatinib for Lung and Thyroid Cancers With RET Gene Mutations or Fusions
On may 8, 2020, selpercatinib was granted accelerated approval for the following indications: Adult patients with metastatic RET fusion-positive non–small cell lung cancer (NSCLC) Adult and pediatric patients ≥ 12 years of age with advanced or metastatic RET-mutant medullary thyroid cancer who...
Andrew E. Aplin, PhD, Receives Humanitarian Award From the Melanoma Research Foundation
The Sidney Kimmel Cancer Center—Jefferson Health (SKCC) recently announced that Andrew E. Aplin, PhD, was being recognized with the Melanoma Research Foundation Humanitarian Award. Dr. Aplin is the Kalbach-Newton Professor in Cancer Research, Enterprise Associate Director for Basic Research, and...
Expert Point of View: Scott T. Tagawa, MD, MS
Discussant Scott T. Tagawa, MD, MS, of Weill Cornell Medicine, New York, agreed that prostate-specific membrane antigen (PSMA)-targeted positron-emission tomography (PET) is the wave of the future, but data on long-term outcomes are needed, he said. “We are all aware of the deficiencies of imaging ...
Ursula A. Matulonis, MD, on Ovarian Cancer: Roundup of Studies on Olaparib, Cediranib, Mirvetuximab Soravtansine, Bevacizumab, and Pembrolizumab
Ursula A. Matulonis, MD, of Dana-Farber Cancer Institute, discusses three important studies focusing on newer therapies for patients with recurrent platinum-sensitive, platinum-agnostic, and advanced recurrent ovarian cancers (Abstracts 6003, 6004, and 6005).
Leora Horn, MD, on Thoracic Cancer and COVID-19: How Type of Cancer Therapy May Affect Survival
Leora Horn, MD, of Vanderbilt University, discusses the results of the TERAVOLT study, launched by the Thoracic Cancers International COVID-19 Collaboration. It examined the impact of specific chemotherapy and immunotherapy regimens on hospitalization and risk of death in patients with thoracic...
Daniel P. Petrylak, MD, on Prostate Cancer: First-in-Human Study of ARV-110 Shows Antitumor Activity
Daniel P. Petrylak, MD, of the Yale Cancer Center, discusses early data on ARV-110, an androgen receptor proteolysis–targeting chimera degrader, demonstrating antitumor activity in metastatic castration-resistant prostate cancer after treatment with enzalutamide and abiraterone (Abstract 3500).
Andres Poveda, MD, on Ovarian Cancer: Assessing Maintenance Olaparib
Andres Poveda, MD, of Initia Oncology, discusses phase III results from the SOLO2 trial, which showed that, compared with placebo, maintenance olaparib improved median overall survival by 12.9 months in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA mutation (Abstract 6002).
Ibrutinib in Combination With Rituximab in Chronic Lymphocytic Leukemia
On April 21, 2020, ibrutinib was granted an expanded indication for use in combination with rituximab for the initial treatment of adult patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL).1,2 The recommended dosage of ibrutinib in CLL/SLL is 420 mg, once daily,...
Five New Recipients of NCCN Foundation Young Investigator Awards
The National Comprehensive Cancer Network® (NCCN®) and the NCCN Foundation announced five new recipients for the 10th annual NCCN Foundation Young Investigator Awards Program. The honorees will receive up to $150,000 in funding to study ways to improve care and help find cures for people with...
Cancer and COVID-19: Considerations About Neutropenia, Anemia, and Thrombocytopenia
GUEST EDITORS Dr. Abutalib is Associate Director of the Hematology and Cellular Therapy Program and Director of the Clinical Apheresis Program at Cancer Treatment Centers of America, Zion, Illinois; Associate Professor at the Roseland Franklin University of Medicine and Science; and Founder and...
From Ecuador to Nashville to Dallas: An Early Path to a Career in Medicine for Carlos L. Arteaga, MD
Carlos L. Arteaga, MD, is Director of the Harold C. Simmons Cancer Center and Associate Dean for Oncology Programs, UT Southwestern Medical Center (UTSW), Dallas. He is an expert in breast cancer who has authored more than 350 publications in the areas of oncogenes in breast tumors, targeted...
Howard A. Burris III, MD, FACP, FASCO, on the ASCO20 Virtual Scientific Program: After Action Report
Howard A. Burris III, MD, FACP, FASCO, Immediate Past President of ASCO and current Society Board Chair, talks about how the meeting went, with its record-breaking attendance and new format.
In Biochemically Recurrent Prostate Cancer, PSMA-Targeted PET/CT Imaging May Be Useful
Positron-emission tomography/computed tomography (PET/CT) imaging with the prostate-specific membrane antigen (PSMA)-targeted radiotracer fluorine F-18 DCFPyL (PyL) successfully identified areas of occult metastasis in men with biochemically recurrent metastatic castration-resistant prostate...
Olaparib Plus Bevacizumab in Maintenance Treatment for Ovarian, Fallopian Tube, or Primary Peritoneal Cancers
On May 8, 2020, olaparib was granted an expanded indication to include use in combination with bevacizumab for first-line maintenance treatment of adult patients with advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in complete or partial response to first-line...
Relationship Between Type 3c Diabetes and Pancreatic Cancer
According to the results of a European case-control study published by Molina-Montes et al in the journal Gut, one of the most recently identified types of diabetes—type 3c, or pancreatogenic diabetes—could also be an early manifestation of pancreatic cancer. Pancreatic cancer has a high mortality...
Rates of Testicular Cancer Rising Among Racial/Ethnic Minorities in the United States
Between 2001 and 2016 in the United States, Asian/Pacific Islander men experienced the greatest increase in the incidence of testicular germ cell tumors, followed by Hispanic and American Indian/Alaska Native men, according to a study published by Ghazarian et al in Cancer Epidemiology, Biomarkers...
Safety and Patient-Reported Outcomes From the IMpower150 Trial in Metastatic Nonsquamous NSCLC
A safety and patient-reported outcome analysis from the IMpower150 trial, reported in the Journal of Clinical Oncology by Martin Reck, PhD, and colleagues, indicated that atezolizumab plus bevacizumab and chemotherapy appeared to be a manageable and tolerable regimen when compared with atezolizumab ...
Phyllis F. Cantor Center for Research in Nursing and Patient Care Services Awarded $1.3 Million for Cancer Projects
Nurse-scientists from the Phyllis F. Cantor Center for Research in Nursing and Patient Care Services at Dana-Farber Cancer Institute, Boston, received more than $1.3 million in funding for two separate research projects. The American Association for Cancer Research announced that in partnership...
Pamela Hull, PhD, Appointed Associate Director of Population Science and Community Impact at Kentucky Cancer Center
The University of Kentucky Markey Cancer Center announced that medical sociologist Pamela Hull, PhD, will join the center as Associate Director of Population Science and Community Impact. She will also serve as the William Stamps Farish Endowed Chair in Cancer Research and join the University of...
Outcomes With Minimally Invasive vs Open Esophagectomy in Routine Practice
In a Dutch study reported in the Journal of Clinical Oncology, Markar et al found that routine use of minimally invasive vs open esophagectomy for esophageal cancer was associated with increased risk of pulmonary complications and other adverse outcomes, contrary to the findings of the clinical...
Impact of the COVID-19 Pandemic on Pediatric Cancer Care in Latin America
In a commentary published in The Lancet Oncology, Vasquez et al presented results of a survey of pediatric oncologists/hematologists across Latin America, which showed an adverse early impact of the COVID-19 pandemic on pediatric cancer care. Study Details The study included a cross-sectional...
Sacituzumab Govitecan-hziy for Previously Treated Metastatic Triple-Negative Breast Cancer
On April 22, 2020, the antibody-drug conjugate sacituzumab govitecan-hziy was granted accelerated approval for treatment of adult patients with metastatic triple-negative breast cancer who have received at least two prior therapies for metastatic disease.1,2 Supporting Efficacy Data Approval was...
Expert Point of View: Padmanee Sharma, MD, PhD
Discussant of the IMbassador250 trial, Padmanee Sharma, MD, PhD, of The University of Texas MD Anderson Cancer Center, Houston, said: “These data indicate that neither anti–PD-1/PD-L1 monotherapy or the combination of anti–PD-1/PD-L1 with enzalutamide is likely to provide improved clinical benefit ...
IMbassador250 Trial: No Survival Benefit With Atezolizumab and Enzalutamide in Metastatic Prostate Cancer
The addition of the checkpoint inhibitor atezolizumab to enzalutamide failed to improve overall survival compared with enzalutamide alone in men with metastatic castration-resistant prostate cancer in the phase III IMbassador250 trial, according to results presented at the 2020 American Association ...
PSA Level Prior to Salvage Radiotherapy: Tailoring Delivery of ADT to Men With Prostate Cancer Most Likely to Benefit
In a recent article in JAMA Oncology, reviewed in this issue of The ASCO Post, Dess et al present an important analysis to help guide decision-making in the setting of salvage radiotherapy in prostate cancer.1 This secondary analysis assessed the association of prostate-specific antigen (PSA)...
Presalvage Radiotherapy PSA Levels and Outcomes With Long-Term Antiandrogen Therapy in Prostate Cancer
In an analysis from the NRG/RTOG 9601 trial reported in JAMA Oncology,1Robert T. Dess, MD, of the Department of Radiation Oncology, University of Michigan, Ann Arbor, and colleagues found that men with higher prostate-specific antigen (PSA) presalvage radiotherapy levels after prostatectomy had a...
Francis Collins, MD, PhD, Awarded 2020 Templeton Prize for Integrating Faith and Reason Into Science
Geneticist and physician Francis Collins, MD, PhD, Director of the National Institutes of Health (NIH) and career-long advocate for the integration of faith and reason, was recently announced as the 2020 Templeton Prize Laureate. Dr. Collins was selected as the 2020 Laureate by the prize judges...
Addition of CD38-Directed Antibody Isatuximab to Multiple Myeloma Armamentarium
The treatment approaches to multiple myeloma have significantly changed over the past decade with the introduction of many new active agents. Among them, the monoclonal antibodies have been one of the most exciting advances in myeloma, complementing their success in other hematologic cancers. In...
Conquer Cancer Names 2020 Women Who Conquer Cancer Mentorship Award Recipients
Conquer Cancer, the ASCO Foundation®, has named Dawn L. Hershman, MD, MS, FASCO, as the 2020 Hologic, Inc Endowed Women Who Conquer Cancer Mentorship Award recipient, and Lillian L. Siu, MD, FRCPC, FASCO, as the International Women Who Conquer Cancer Mentorship Award recipient. The 2020 Women Who ...
Spotlight on Women Who Conquer Cancer
Women Who Conquer Cancer (WWCC) is a groundbreaking program that is committed to supporting early-career women researchers by funding research grants through Conquer Cancer, the ASCO Foundation®. Since its inception 7 years ago, the program has raised nearly $5 million, funded 27 Young Investigator ...
Men of Color Remain Underrepresented in Prostate Cancer Clinical Trials
An analysis of 59 prostate cancer clinical trials based in North America and Europe found that the vast majority of enrollees were non-Hispanic white men, according to a study published by Rencsok et al in Cancer Epidemiology, Biomarkers & Prevention. The proportion of white participants in...
Study Explores Adding Trastuzumab to Radiotherapy for Women With HER2-Positive DCIS
The addition of trastuzumab to radiotherapy did not reach the protocol objective of a 36% reduction in the ipsilateral breast tumor recurrence rate for women with HER2-positive ductal carcinoma in situ (DCIS) in the NRG Oncology clinical trial NSABP B-43. The trial did find a modest (19%) reduction ...
Nivolumab vs Bevacizumab in Recurrent Glioblastoma
As reported in JAMA Oncology by David A. Reardon, MD, and colleagues, the phase III CheckMate 143 trial showed no difference in overall survival among adult patients with a first recurrence of glioblastoma treated with nivolumab vs bevacizumab following standard radiation and temozolomide therapy. ...
Pembrolizumab, Trastuzumab, and Chemotherapy in HER2-Positive Metastatic Esophagogastric Cancer
In a single-center phase II trial reported in The Lancet Oncology, Janjigian et al found that the addition of pembrolizumab to trastuzumab and chemotherapy showed activity in the first-line treatment of HER2-positive metastatic esophagogastric cancer. Study Details The investigator-initiated trial...
Genomic Characteristics of Smoldering Multiple Myeloma and Risk of Progression
In a study reported in the Journal of Clinical Oncology, Mark Bustoros, MD, and colleagues identified genomic features of smoldering multiple myeloma associated with a higher risk of progression to multiple myeloma and found that alterations that drive disease progression are already present at the ...
Plenary Research From the ASCO20 Virtual Scientific Program: Part 1
This week, we’ll be hearing from the authors of three late-breaking abstracts presented in the Plenary program at the ASCO20 Virtual Scientific Program. Their findings highlight significant advances in lung cancer, bladder cancer, and colorectal cancer.
RET Kinase Inhibitor for Patients With Solid Tumors and RET Genetic Fusions
The RET inhibitor pralsetinib showed activity in patients with a broad variety of tumors harboring RET gene fusions, according to results from the phase I/II ARROW trial, presented by Vivek Subbiah, MD, and colleagues during the ASCO20 Virtual Scientific Program (Abstract 109). “This trial shows...
Results From an Oncology Hospital-at-Home Evaluation
Researchers at Huntsman Cancer Institute (HCI) at the University of Utah presented the first outcomes evaluation of an adult oncology hospital-at-home program during the ASCO20 Virtual Scientific Program (Abstract 7000). The study evaluated patients participating in HCI's Huntsman at Home program....
Risk-Adapted Dose-Adjusted EPOCH-R for Previously Untreated Adult Patients With Burkitt Lymphoma
In a phase II study reported in the Journal of Clinical Oncology, Roschewski et al found that risk-adapted dose-adjusted etoposide doxorubicin, cyclophosphamide, vincristine, prednisone, and rituximab (EPOCH-R) produced high event-free survival rates among high- and low-risk adult patients with...
Adjuvant Nivolumab/Ipilimumab or Nivolumab Alone vs Placebo in Patients With Resected Stage IV Melanoma
In an interim analysis of the German phase II IMMUNED study reported in The Lancet, Zimmer et al found that adjuvant therapy with nivolumab/ipilimumab or nivolumab alone significantly prolonged recurrence-free survival vs placebo in patients with resected stage IV melanoma and no evidence of...
Trastuzumab Deruxtecan vs Chemotherapy for Previously Treated Patients With HER2-Positive Advanced Gastric Cancer
Results of the phase II DESTINY-Gastric01 study—reported at the ASCO20 Virtual Scientific Program (Abstract 4513) and published in The New England Journal of Medicine, by Kohei Shitara, MD, of the National Cancer Center Hospital East, Kashiwa, and colleagues—found that the antibody-drug conjugate...
Expert Point of View: Scott T. Tagawa, MD, MS
Discussant Scott T. Tagawa, MD, MS, of Weill Cornell Medicine, New York, congratulated Dr. Hofman and coauthors on this first randomized trial any PSMA-targeted therapy, and was cautiously optimistic about the targeted radioligand treatment being adopted as post-docetaxel therapy in men with...
Lutetium-177–Labeled PSMA-617 Improves PSA Response in First Analysis From TheraP Trial in Metastatic Prostate Cancer
Initial results of the randomized phase II TheraP trial show that therapy directed to prostate-specific membrane antigen (PSMA) with lutetium-177–labeled PSMA-617 (LuPSMA) significantly improved prostate-specific antigen (PSA) response compared with cabazitaxel in men with metastatic...
Tingyan Shi, MD, PhD, on Ovarian Cancer: Secondary Cytoreductive Surgery for Recurrent Disease
Tingyan Shi, MD, PhD, of Zhongshan Hospital, Fudan University, discusses study results that showed secondary cytoreductive surgery in selected patients extended progression-free survival and might contribute to long-term survival (Abstract 6001).
Michael J. Morris, MD, on Prostate Cancer: Impact of PSMA-Targeted Imaging on Clinical Management
Michael J. Morris, MD, of Memorial Sloan Kettering Cancer Center, discusses phase III data from the CONDOR trial, which showed that PSMA-targeted PET scans detected and localized occult disease in most men with biochemically recurrent prostate cancer presenting with negative or equivocal...
Study Finds Substantial Racial/Ethnic Disparities in Lost Earnings From Cancer Mortality
Disparities in cancer mortality rates between black and white Americans date back more than 60 years. Now, a study by the American Cancer Society comparing person-years of life lost and lost earnings due to premature cancer mortality by race/ethnicity has quantified the economic burden due to...
Androgen Deprivation With Oral Relugolix vs Leuprolide in Advanced Prostate Cancer: HERO Trial
As reported at the ASCO20 Virtual Scientific Program (Abstract 5602) and in The New England Journal of Medicine by Shore et al, the phase III HERO trial showed sustained castrate testosterone levels and lower risk of major cardiovascular events with the oral gonadotropin-releasing hormone...
Does Treatment With Immune Checkpoint Inhibitors Cause Flare-ups in Patients With Preexisting IBD or Microscopic Colitis?
In a retrospective analysis reported in JCO Oncology Practice, Grover et al found that enterocolitis flares occurred in approximately one-quarter of patients with preexisting inflammatory bowel disease (IBD) or microscopic colitis who received immune checkpoint inhibitors for the treatment of solid ...
Liposomal Daunorubicin and Cytarabine Followed by FLAG for Pediatric Relapsed AML
In a phase I/II Children’s Oncology Group study (AAML1421) reported in the Journal of Clinical Oncology, Cooper et al identified the phase II dose of CPX-351, a liposomal preparation of daunorubicin and cytarabine, and found that a regimen consisting of CPX-351 followed by fludarabine, cytarabine,...
